Abstract Objective To study the differentially expressed mRNAs between MYCN-amplified neuroblastoma (NB) and non-amplified NB, to screen out the genes which can be used to predict the prognosis of MYCN-amplified NB, and to analyze their value in predicting prognosis. Methods NB transcriptome data and the clinical data of children were obtained from the TARGET database. According to the presence or absence of MYCN amplification, the children were divided into two groups:MYCN amplification (n=33) and non-MYCN amplification (n=121). The expression of mRNAs was compared between the two groups to obtain differentially expressed genes (DEGs). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genome (KEGG) analysis was performed to investigate the main functions of DEGs. The Cox proportional-hazards regression model analysis was used to investigate the genes influencing the prognosis of MYCN-amplified NB. The children were divided into a high-risk group (n=77) and a low-risk group (n=77) based on the median of risk score. A survival analysis was used to compare survival rate between the two groups. The receiver operating characteristic (ROC) curve was used to investigate the value of risk score in predicting the prognosis of children with MYCN-amplified NB. Results A total of 582 DEGs were screened out, and they were involved in important biological functions such as ribosome composition, expression of cell adhesion molecules, and activity of membrane receptor protein. The multivariate Cox regression model analysis showed that FLVCR2, SCN7A, PRSS12, NTRK1, and XAGE1A genes had a marked influence on the prognosis of the children with NB in the MYCN amplification group (P < 0.05). The survival analysis showed that the high-risk group had a significantly lower overall survival rate than the low-risk group (P < 0.05). The ROC curve analysis showed that risk score had a certain value in predicting the prognosis of the children with NB in the MYCN amplification group (P < 0.05), with an area under the ROC curve of 0.729, an optimal cut-off value of 1.316, a sensitivity of 53.2%, and a specificity of 84.4%. Conclusions The mRNA expression of FLVCR2, SCN7A, PRSS12, NTRK1, and XAGE1A genes can be used as biomarkers to predict the prognosis of MYCN-amplified NB, which can help to refine clinical risk stratification.
FAN Xu,LU Hong-Ting,HOU Lin et al. A comprehensive analysis of potential prognostic biomarkers for MYCN-amplified neuroblastoma[J]. CJCP, 2020, 22(3): 262-268.
FAN Xu,LU Hong-Ting,HOU Lin et al. A comprehensive analysis of potential prognostic biomarkers for MYCN-amplified neuroblastoma[J]. CJCP, 2020, 22(3): 262-268.
Campbell K, Gastier-Foster JM, Mann M, et al. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma:a report from the Children's Oncology Group[J]. Cancer, 2017, 123(21):4224-4235.
[6]
Maris JM. Recent advances in neuroblastoma[J]. N Engl J Med, 2010, 362(23):2202-2211.
[7]
Nikolayeva O, Robinson MD. edgeR for differential RNA-seq and ChIP-seq analysis:an application to stem cell biology[J]. Methods Mol Biol, 2014, 1150:45-79.
[8]
Rosenblum M, Qian T, Du Y, et al. Multiple testing procedures for adaptive enrichment designs:combining group sequential and reallocation approaches[J]. Biostatistics, 2016, 17(4):650-662.
[9]
Maere S, Heymans K, Kuiper M. BiNGO:a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks[J]. Bioinformatics, 2005, 21(16):3448-3449.
[10]
Xia L, Wang Y, Meng Q, et al. Integrated bioinformatic analysis of a competing endogenous RNA network reveals a prognostic signature in endometrial cancer[J]. Front Oncol, 2019, 9:448.
[11]
Fletcher JI, Ziegler DS, Trahair TN, et al. Too many targets, not enough patients:rethinking neuroblastoma clinical trials[J]. Nat Rev Cancer, 2018, 18(6):389-400.
[12]
Delaidelli A, Negri GL, Jan A, et al. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation[J]. Cell Death Differ, 2017, 24(9):1564-1576.
[13]
Ruiz-Pérez MV, Henley AB, Arsenian-Henriksson M. The MYCN protein in health and disease[J]. Genes (Basel), 2017, 8(4). pii:E113.
[14]
Meyer E, Ricketts C, Morgan NV, et al. Mutations in FLVCR2 are associated with proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome (Fowler syndrome)[J]. Am J Hum Genet, 2010, 86(3):471-478.
[15]
Ke CB, He WS, Li CJ, et al. Enhanced SCN7A/Nax expression contributes to bone cancer pain by increasing excitability of neurons in dorsal root ganglion[J]. Neuroscience, 2012, 227:80-89.
[16]
Mitsui S, Osako Y, Yuri K. Mental retardation-related protease, motopsin (prss12), binds to the BRICHOS domain of the integral membrane protein 2a[J]. Cell Biol Int, 2014, 38(1):117-123.
[17]
Pajtler KW, Rebmann V, Lindemann M, et al. Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells[J]. Int J Cancer, 2013, 133(4):908-919.
[18]
Li Z, Takenobu H, Setyawati AN, et al. EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications[J]. Oncogene, 2018, 37(20):2714-2727.
[19]
Schramm A, Schowe B, Fielitz K, et al. Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome[J]. Br J Cancer, 2012, 107(8):1409-1417.
